Accessibility Menu
IN8bio logo

IN8bio(NASDAQ) INAB

Current Price$1.23
Market Cap$12.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-42%
1 Month-12%
IN8bio last closing stock price
MetricPriceDate
Last closeUSD 1.262026-07-20
IN8bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.97%USD 1.342026-07-13
1 month-11.89%USD 1.432026-06-18
3 month-14.86%USD 1.482026-04-21
Year to date-46.15%USD 2.342025-12-31
1 year-41.94%USD 2.172025-07-18
3 year-97.5%USD 50.402023-07-21
Since inception-99.58%USD 300.002021-07-30

IN8bio Financials at a Glance

Market Cap

$12.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$18.98M

EPS (TTM)

-$2.85

P/E Ratio

-0.44

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$1.23

Volume

139

Open

$1.24

Previous Close

$1.26

Daily Range

$1.23 - $1.24

52-Week Range

$1.17 - $2.73

Estimated Earnings Date

Aug 6, 2026

INAB News

Foolcom-Featured.png

IN8bio (INAB) Q2 Loss Narrows 77%

Motley Fool Markets TeamAug 7, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About IN8bio

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer and autoimmune diseases. Its innovative approach utilizes the unique properties of gamma-delta T cells, which bridge innate and adaptive immune responses, to target and potentially eliminate a wide range of tumor cells.

Products and Services

INB-100: Allogeneic gamma-delta T cell therapy for hematologic malignancies post stem cell transplant.

INB-200: Genetically modified, autologous gamma-delta T cell therapy for glioblastoma (GBM).

INB-400: Suspended Phase 2 trial assessing gamma-delta T cell therapy for GBM.

INB-600: Proprietary T cell engager platform aimed at solid tumors and autoimmune diseases.

Preclinical pipeline: Including INB-300 with non-signaling CAR constructs and INB-500 involving iPSC-derived gamma-delta T cells.

What Makes IN8bio, Inc. Special

IN8bio's focus on gamma-delta T cells allows it to leverage both the innate and adaptive immune systems for a potentially broader and more robust response against tumors. Its proprietary DeltEx platform enhances gamma-delta T cell efficacy and persistence, setting it apart in the competitive oncology landscape.

Five Things You Need to Know

Gamma-delta T cells naturally target and kill tumor cells while evading some common immunotherapy challenges.

IN8bio's pipeline includes products targeting both hematologic cancers and solid tumors like glioblastoma.

The company holds a strong patent portfolio that protects its innovations in gamma-delta T cell therapies.

IN8bio faces financial challenges, with recent measures taken to preserve cash and increase flexibility.

Strategic partnerships and potential collaborations are key components of IN8bio's growth strategy, aiming to expedite development and broaden impact.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

18

CEO

William T. Ho, MBA

Website

www.in8bio.com

Headquarters

New York City, NY 10118, US

INAB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-96.39%

Return on Capital

-65.46%

Return on Assets

-72.26%

Earnings Yield

-2.27%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$12.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.85M

Volume

139

Avg. Volume

59.50K

Financials (TTM)

Gross Profit

-$500.00K

Operating Income

-$19.16M

EBITDA

-$16.85M

Operating Cash Flow

-$14.54M

Capital Expenditure

-$9.00K

Free Cash Flow

-$14.55M

Cash & ST Invst.

$21.94M

Total Debt

$2.35M

IN8bio Performance Analysis

IN8bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
IN8bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
IN8bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -40.8174.3%
20232023-12-31USD -30.14-26.1%
20242024-12-31USD -17.05-43.4%
20252025-12-31USD -4.44-73.9%
IN8bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-1764.7%
Q32025-09-3031.5%
Q42025-12-3140.0%
Q12026-03-31-127.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$500.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$12.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$689.29K

N/A

Employees

18

N/A

Net Income

-$5.09M

+8.3%

EBITDA

-$4.59M

+8.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$21.94M

+84.6%

Total Debt

$2.35M

-44.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.33M

-56.3%

Short Term Debt

$1.03M

-16.9%

Return on Assets

-72.26%

N/A

Return on Invested Capital

-79.46%

N/A

Free Cash Flow

-$4.96M

-58.7%

Operating Cash Flow

-$4.95M

-58.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PHIOPhio Pharmaceuticals Corp.
$1.13+4.63%
KPRXKiora Pharmaceuticals, Inc.
$2.55-2.12%
APVOAptevo Therapeutics Inc.
$4.43-6.83%
RNAZTransCode Therapeutics, Inc.
$8.33-4.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.27+0.01%
MARAMara Holdings
$12.15+0.04%
SOFISoFi Technologies
$17.39+0.02%
HLHecla Mining
$15.18+0.06%

Questions About INAB

What is the current price of IN8bio?

IN8bio is trading at $1.23 per share.

What is the 52-week range for IN8bio?

Over the past 52 weeks, IN8bio has traded between $1.17 and $2.73.

How much debt does IN8bio have?

As of the most recent reporting period, IN8bio reported total debt of $2.35M.

How much cash does IN8bio have on hand?

IN8bio reported $21.94M in cash and cash equivalents in its most recent financial results.

What is IN8bio’s dividend yield?

IN8bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services